Lipo-PEG-PEI complex encapsulated antitumor drug for colorectal cancer therapy

• Main Authors: Chang, Jung, 張蓉
• Other Authors: 廖光文
• Format: Others
• Language: en_US
• Published: 2015
• Online Access: http://ndltd.ncl.edu.tw/handle/4f6787

碩士 === 國立交通大學 === 生物科技學系 === 103 === CR1 is a derivative of the plant lignan nordihydroguaiaretic acid (NDGA). It has been proposed that the parent compound and its derivatives inhibit the interaction between the transcription factor Sp1 and its DNA-binding site via DNA groove-binding. Furthermore, Sp1 has highly related to colorectal cancer development and progression. Therefore, CR1 is a potential anticancer agent in colorectal cancer therapy, but CR1 also has side effect to normal tissues. Because of its high cytotoxicity, liposome encapsulation may reduce the cytotoxicity of CR1 to normal tissues, but keep the cytotoxicity for tumor cells. Colorectal carcinoma, cancer of the colon and rectum, is the second leading cause of cancer death worldwide in women and the third leading cause of cancer death worldwide in men. Nowadays, therapy of colorectal cancer is only moderately successful for late-stage and is often limited by severe side effects and dose limiting toxicity. Hence, it is needed a new chemotherapy agent in colorectal cancer. My purpose is to use Lipo-PEG-PEI complex (LPPC) encapsulated CR1 to reduce cytotoxicity in normal tissues, and improve therapeutic efficacy for colorectal cancer. In my results, the protocol for the formation of LPPC/CR1 was optimal. LPPC/CR1 had an average size less than 200 nm and a zeta potential of approximately 35 mV. In addition, this study also showed the antitumor effects of LPPC/CR1 for colorectal cancer in vitro and in vivo. These results indicate that the LPPC/CR1 complex may supply a feasible strategy for the advanced colorectal cancer therapy in the future.